Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. In addition, the company is developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. Mission:?We acquire, develop and efficiently commercialize novel therapeutics to give hope to people suffering from orphan diseases. With a commitment to compassionate care, we focus on creating value for everyone who benefits from our work.
51 to 200 Employees
TypeCompany - Public
Revenue$100 to $500 million (USD)
IndustryBiotech & Pharmaceuticals
CompetitorsUnknown
Founded